Preclinical Studies in the Pharmaceutical Development Cycle
https://doi.org/10.30895/1991-2919-2024-14-3-248-250
Abstract
The ultimate goal of preclinical studies is to generate data that can be used to make conclusions about the potential effects of a new medicine on the human body and to properly proceed to clinical trials. In this interview, Marina N. Makarova, Doctor of Medical Sciences, Director of the RMC “HOME OF PHARMACY”, shares her views on conducting preclinical studies in Russia.
About the Author
M. N. MakarovaRussian Federation
Marina N. Makarova, Dr. Sci. (Med.)
3/245 Zavodskaya St., Kuzmolovsky urban-type settlement, Vsevolozhsky district, Leningrad region 188663
Supplementary files
Review
For citations:
Makarova M.N. Preclinical Studies in the Pharmaceutical Development Cycle. Regulatory Research and Medicine Evaluation. 2024;14(3):248-250. (In Russ.) https://doi.org/10.30895/1991-2919-2024-14-3-248-250